StemCyte's Groundbreaking RegeneCyte® Program Receives FDA Clearance for Long COVID Patients StemCyte, Inc. announces FDA clearance for their Expanded Access program that allows Long COVID patients to access RegeneCyte®, a promising new therapy.

StemCyte's Groundbreaking RegeneCyte® Program Receives FDA Clearance for Long COVID Patients #United_States #StemCyte #REGENECYTE #Baldwin_Park #Long_COVID

StemCyte Introduces Innovative Cord Blood Insurance Model in Taiwan to Enhance Cell Therapy Access StemCyte has launched Taiwan's first insurance-linked public cord blood access, transforming cell therapy accessibility for families. Find out more!

StemCyte Introduces Innovative Cord Blood Insurance Model in Taiwan to Enhance Cell Therapy Access #Taiwan #StemCyte #Baldwin_Park #Taishin_Life

Caelux® Delivers First Shipment of Innovative Active Glass Technology for Solar Energy Expansion Caelux® has successfully shipped its first commercial Active Glass technology, destined to enhance solar efficiency and reduce costs.

Caelux® Delivers First Shipment of Innovative Active Glass Technology for Solar Energy Expansion #United_States #Baldwin_Park #Solar_Technology #Caelux #Active_Glass

Aaron Thurlow Appointed as Senior Vice President at Caelux® to Drive Global Sales and Marketing Strategies Caelux® has welcomed Aaron Thurlow as the new Senior Vice President of Sales and Marketing to enhance commercialization and revenue growth across the globe.

Aaron Thurlow Appointed as Senior Vice President at Caelux® to Drive Global Sales and Marketing Strategies #United_States #solar_energy #Baldwin_Park #Caelux #Aaron_Thurlow

Demetree Global Expands Footprint in Central Florida with New Office Acquisition Demetree Global enhances its presence in Central Florida by acquiring a prime Baldwin Park office building, reflecting its investment commitment.

Demetree Global Expands Footprint in Central Florida with New Office Acquisition #United_States #Baldwin_Park #Orlando #Demetree_Global

Caelux® Named 2025 Solar Technology Company of the Year at CleanTech Breakthrough Awards Caelux® has been honored as the Solar Technology Company of the Year at the 2025 CleanTech Breakthrough Awards, recognizing its innovative contributions to solar energy.

Caelux® Named 2025 Solar Technology Company of the Year at CleanTech Breakthrough Awards #United_States #Baldwin_Park #Solar_Technology #CleanTech #Caelux

StemCyte Reports 85% Success in Phase IIa Trial Using HPC Cord Blood for Post-COVID Syndrome A recent Phase IIa trial by StemCyte shows remarkable efficacy in treating Post-COVID Syndrome using HPC, Cord Blood, with 85% of patients reporting complete relief from fatigue.

StemCyte Reports 85% Success in Phase IIa Trial Using HPC Cord Blood for Post-COVID Syndrome #USA #StemCyte #Baldwin_Park #HPC #Post-COVID

FDA Greenlights StemCyte's REGENECYTE for Cord Blood Cell Therapy, Ushering in New Possibilities StemCyte's REGENECYTE™ Cord Blood Cell Therapy receives FDA approval, marking a pivotal moment for regenerative medicine and expanding treatment options for blood disorders.

FDA Greenlights StemCyte's REGENECYTE for Cord Blood Cell Therapy, Ushering in New Possibilities #United_States #StemCyte #REGENECYTE #FDA_Approval #Baldwin_Park